Cary J. Claiborne
Chief Executive Officer at Adial Pharmaceuticals Inc
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 2 boards, counting each seat separately. Longest: Adial Pharmaceuticals Inc, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Adial Pharmaceuticals Inc September 17, 202699.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 7, 2026 | Adial Pharmaceuticals Inc | Grant or award | +37,985 | — | — |
| May 23, 2023 | Adial Pharmaceuticals Inc | Grant or award | +420,000 | — | — |
Questions about Cary J. Claiborne
What boards is Cary J. Claiborne on?
Cary J. Claiborne sits on the boards of Adial Pharmaceuticals Inc and NeuroSense Therapeutics Ltd.
What company is Cary J. Claiborne the CEO of?
Cary J. Claiborne is Chief Executive Officer of Adial Pharmaceuticals Inc.
How long has Cary J. Claiborne served on boards?
Our records show at least 4 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.